Provectus Biopharmaceuticals Inc. Signs Memorandum Of Understanding With Sinopharm-China State Institute Of Pharmaceutical Industry, And Sinopharm A-THINK Pharmaceutical Co., Ltd.
8/18/2014 8:03:01 AM
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a Memorandum of Understanding (“MOU”) with Sinopharm-China State Institute of Pharmaceutical Industry (“Sinopharm-CSIPI”), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. (“Sinopharm A-THINK”), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.
Help employers find you! Check out all the jobs and post your resume.
comments powered by